BACKGROUND: Three costimulation blockade-based regimens have been explored after transplantation of hearts from pigs of varying genetic backgrounds to determine whether CTLA4-Ig (abatacept) or anti-CD40mAb+CTLA4-Ig (belatacept) can successfully replace anti-CD154mAb. METHODS: All pigs were on an α1,3-galactosyltransferase gene-knockout/CD46 transgenic (GTKO.CD46) background. Hearts transplanted into Group A baboons (n=4) expressed additional CD55, and those into Group B (n=3) expressed human thrombomodulin (TBM). Immunosuppression included anti-thymocyte globulin with anti-CD154mAb (Regimen 1: n=2) or abatacept (Regimen 2: n=2) or anti-CD40mAb+belatacept (Regimen 3: n=2). Regimens 1 and 2 included induction anti-CD20mAb and continuous heparin. One further baboon in Group B (B16311) received a modified Regimen 1. Baboons were followed by clinical/laboratory monitoring of immune/coagulation parameters. At biopsy, graft failure, or euthanasia, the graft was examined by microscopy. RESULTS: Group A baboons survived 15 to 33 days, whereas Group B survived 52, 99, and 130 days, respectively. Thrombocytopenia and reduction in fibrinogen occurred within 21 days in Group A, suggesting thrombotic microangiopathy (TM), confirmed by histopathology. In Group B, with follow-up for >4 m, areas of myofiber degeneration and scarring were seen in two hearts at necropsy. A T-cell response was documented only in baboons receiving Regimen 2. CONCLUSIONS: The combination of anti-CD40mAb+belatacept proved effective in preventing a T-cell response. The expression of TBM prevented thrombocytopenia and may possibly delay the development of TM and/or consumptive coagulopathy.
BACKGROUND: Three costimulation blockade-based regimens have been explored after transplantation of hearts from pigs of varying genetic backgrounds to determine whether CTLA4-Ig (abatacept) or anti-CD40mAb+CTLA4-Ig (belatacept) can successfully replace anti-CD154mAb. METHODS: All pigs were on an α1,3-galactosyltransferase gene-knockout/CD46 transgenic (GTKO.CD46) background. Hearts transplanted into Group A baboons (n=4) expressed additional CD55, and those into Group B (n=3) expressed humanthrombomodulin (TBM). Immunosuppression included anti-thymocyte globulin with anti-CD154mAb (Regimen 1: n=2) or abatacept (Regimen 2: n=2) or anti-CD40mAb+belatacept (Regimen 3: n=2). Regimens 1 and 2 included induction anti-CD20mAb and continuous heparin. One further baboon in Group B (B16311) received a modified Regimen 1. Baboons were followed by clinical/laboratory monitoring of immune/coagulation parameters. At biopsy, graft failure, or euthanasia, the graft was examined by microscopy. RESULTS: Group A baboons survived 15 to 33 days, whereas Group B survived 52, 99, and 130 days, respectively. Thrombocytopenia and reduction in fibrinogen occurred within 21 days in Group A, suggesting thrombotic microangiopathy (TM), confirmed by histopathology. In Group B, with follow-up for >4 m, areas of myofiber degeneration and scarring were seen in two hearts at necropsy. A T-cell response was documented only in baboons receiving Regimen 2. CONCLUSIONS: The combination of anti-CD40mAb+belatacept proved effective in preventing a T-cell response. The expression of TBM prevented thrombocytopenia and may possibly delay the development of TM and/or consumptive coagulopathy.
Authors: A D Kirk; D M Harlan; N N Armstrong; T A Davis; Y Dong; G S Gray; X Hong; D Thomas; J H Fechner; S J Knechtle Journal: Proc Natl Acad Sci U S A Date: 1997-08-05 Impact factor: 11.205
Authors: Carol J Phelps; Chihiro Koike; Todd D Vaught; Jeremy Boone; Kevin D Wells; Shu-Hung Chen; Suyapa Ball; Susan M Specht; Irina A Polejaeva; Jeff A Monahan; Pete M Jobst; Sugandha B Sharma; Ashley E Lamborn; Amy S Garst; Marilyn Moore; Anthony J Demetris; William A Rudert; Rita Bottino; Suzanne Bertera; Massimo Trucco; Thomas E Starzl; Yifan Dai; David L Ayares Journal: Science Date: 2002-12-19 Impact factor: 47.728
Authors: Donna Kolber-Simonds; Liangxue Lai; Steven R Watt; Maria Denaro; Scott Arn; Monica L Augenstein; Jeffery Betthauser; David B Carter; Julia L Greenstein; Yanhong Hao; Gi-Sun Im; Zhonghua Liu; Greg D Mell; Clifton N Murphy; Kwang-Wook Park; August Rieke; David J J Ryan; David H Sachs; Erik J Forsberg; Randall S Prather; Robert J Hawley Journal: Proc Natl Acad Sci U S A Date: 2004-05-03 Impact factor: 11.205
Authors: Bruce E Loveland; Julie Milland; Peter Kyriakou; Bruce R Thorley; Dale Christiansen; Marc B Lanteri; Mark Regensburg; Maureen Duffield; Andrew J French; Lindsay Williams; Louise Baker; Malcolm R Brandon; Pei-Xiang Xing; Del Kahn; Ian F C McKenzie Journal: Xenotransplantation Date: 2004-03 Impact factor: 3.907
Authors: Stuart L Houser; Kenji Kuwaki; Christoph Knosalla; Frank J M F Dor; Bernd Gollackner; Jane Cheng; Akira Shimizu; Henk-Jan Schuurman; David K C Cooper Journal: Xenotransplantation Date: 2004-09 Impact factor: 3.907
Authors: Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski Journal: Transplantation Date: 2016-02 Impact factor: 4.939
Authors: Tao Li; Whayoung Lee; Hidetaka Hara; Cassandra Long; Mohamed Ezzelarab; David Ayares; Hai Huang; Yi Wang; Charles T Esmon; David K C Cooper; Hayato Iwase Journal: Transplantation Date: 2017-10 Impact factor: 4.939
Authors: Hayato Iwase; Burcin Ekser; Huidong Zhou; Hong Liu; Vikas Satyananda; Rishab Humar; Pooja Humar; Hidetaka Hara; Cassandra Long; Jay K Bhama; Pietro Bajona; Yi Wang; Martin Wijkstrom; David Ayares; Mohamed B Ezzelarab; David K C Cooper Journal: Xenotransplantation Date: 2015-08-21 Impact factor: 3.907
Authors: Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase Journal: Transpl Immunol Date: 2018-08-06 Impact factor: 1.708
Authors: David K C Cooper; Shinichi Matsumoto; Adrian Abalovich; Takeshi Itoh; Nizar I Mourad; Pierre R Gianello; Eckhard Wolf; Emanuele Cozzi Journal: Transplantation Date: 2016-11 Impact factor: 4.939